THBS1 and AL amyloidosis: In agreement, previous studies have shown that the MTR schedule of several drugs, such as vinorelbine, cyclophosphamide, bevacizumab, gemcitabine and temozolomide in solid tumors and in multiple myeloma improves therapeutic outcomes by directing the drug towards the tumor vasculature or by increasing the expression of TSP-1 and limiting angiogenesis and vasculogenesis at the tumor [29].